Integra LifeSciences Hits New 52-Week High at $17.79

Integra LifeSciences Holdings Corp. has reached a significant milestone by hitting a new 52-week high of USD 17.79 on June 5, 2026. This achievement marks a notable point for the small-cap company operating within the Pharmaceuticals & Biotechnology industry. Despite the recent uptick in stock price, Integra LifeSciences has experienced a challenging year, with a performance decline of 44.57%. In contrast, the S&P 500 has shown a robust performance increase of 24.32% during the same period. The company's market capitalization stands at USD 762 million, reflecting its small-cap status. Integra LifeSciences maintains a price-to-earnings (P/E) ratio of 7.00, which is indicative of its valuation relative to earnings. Additionally, the company has a return on equity of 10.43%, suggesting effective management of shareholder equity. With a price-to-book ratio of 0.73 and a debt-to-equity ratio of 1.54, Integra LifeSciences Holdings Corp. continues to navigate its financial landscape while achieving this new price milestone.